中国肝硬化的当前研究。
Current research of hepatic cirrhosis in China.
作者信息
Yao Xi-Xian, Jiang Shu-Lin, Yao Dong-Mei
机构信息
Department of Gastroenterology of Internal Medicine, Second Hospital, Hebei Medical University, Shijiazhuang 050000, Hebei Province, China.
出版信息
World J Gastroenterol. 2005 Feb 7;11(5):617-22. doi: 10.3748/wjg.v11.i5.617.
Abstract
Hepatic cirrhosis is a common disease that poses a serious threat to public health, and is characterized by chronic, progressive and diffuse hepatic lesions preceded by hepatic fibrosis regardless of the exact etiologies. In recent years, considerable achievements have been made in China in research of the etiopathogenesis, diagnosis and especially the treatment of hepatic fibrosis, resulting in much improved prognosis of hepatic fibrosis and cirrhosis. In this paper, the authors review the current status of research in hepatic fibrosis, cirrhosis and their major complications.
摘要
肝硬化是一种对公众健康构成严重威胁的常见疾病，其特征是无论确切病因如何，在肝纤维化之前出现慢性、进行性和弥漫性肝损伤。近年来，中国在肝纤维化的病因发病机制、诊断尤其是治疗研究方面取得了相当大的成就，肝纤维化和肝硬化的预后有了很大改善。本文作者综述了肝纤维化、肝硬化及其主要并发症的研究现状。
相似文献
1
Current research of hepatic cirrhosis in China.中国肝硬化的当前研究。
World J Gastroenterol. 2005 Feb 7;11(5):617-22. doi: 10.3748/wjg.v11.i5.617.
2
Fibrosis and cirrhosis reversibility: clinical features and implications.纤维化和肝硬化的可逆性：临床特征及意义
Clin Liver Dis. 2008 Nov;12(4):901-13, x. doi: 10.1016/j.cld.2008.07.006.
3
[Research advances in the treatment of hepatic fibrosis].肝纤维化治疗的研究进展
Zhonghua Gan Zang Bing Za Zhi. 2017 Aug 20;25(8):566-570. doi: 10.3760/cma.j.issn.1007-3418.2017.08.003.
4
[Consensus on the diagnosis and therapy of hepatic fibrosis in].[关于肝纤维化诊断与治疗的共识]
Zhonghua Gan Zang Bing Za Zhi. 2019 Sep 20;27(9):657-667. doi: 10.3760/cma.j.issn.1007-3418.2019.09.001.
5
Consensus on the diagnosis and treatment of hepatic fibrosis (2019).肝纤维化诊断与治疗的专家共识（2019 年）。
J Dig Dis. 2020 Mar;21(3):127-138. doi: 10.1111/1751-2980.12854.
6
Dental management of patients with end-stage liver disease.终末期肝病患者的牙科管理。
Dent Clin North Am. 2006 Oct;50(4):563-90, vii. doi: 10.1016/j.cden.2006.06.007.
7
Chinese consensus on the management of liver cirrhosis.《肝硬化诊治专家共识》
J Dig Dis. 2024 Jun;25(6):332-352. doi: 10.1111/1751-2980.13294. Epub 2024 Jul 23.
8
Diagnosis and epidemiology of cirrhosis.肝硬化的诊断与流行病学
Med Clin North Am. 2009 Jul;93(4):787-99, vii. doi: 10.1016/j.mcna.2009.03.002.
9
Presentation and complications associated with cirrhosis of the liver.肝硬化的临床表现及相关并发症。
Curr Med Res Opin. 2015 May;31(5):925-37. doi: 10.1185/03007995.2015.1021905.
10
[Hepatic fibrosis: physiopathology and biological diagnosis].[肝纤维化：生理病理学与生物学诊断]
Pathol Biol (Paris). 1999 Nov;47(9):886-94.
引用本文的文献
1
Quercetin prevents hepatic fibrosis by inhibiting hepatic stellate cell activation and reducing autophagy via the TGF-β1/Smads and PI3K/Akt pathways.槲皮素通过抑制肝星状细胞活化和减少自噬，通过 TGF-β1/Smads 和 PI3K/Akt 途径预防肝纤维化。
Sci Rep. 2017 Aug 24;7(1):9289. doi: 10.1038/s41598-017-09673-5.
2
The association between clinical symptoms, laboratory findings and serum endothelin 1 concentrations, in cirrhotic patients with and without hepatopulmonary syndrome.肝硬化合并和不合并肝肺综合征患者的临床症状、实验室检查结果与血清内皮素-1浓度之间的关联。
Gastroenterol Hepatol Bed Bench. 2012 Winter;5(Suppl 1):S13-9.
3
Pre-existing cirrhosis is associated with increased mortality of traumatic patients: analysis of cases from a trauma center in east China.既往肝硬化与创伤患者死亡率增加相关：来自中国东部一家创伤中心的病例分析。
World J Gastroenterol. 2007 Nov 14;13(42):5654-8. doi: 10.3748/wjg.v13.i42.5654.
本文引用的文献
1
Effects of tetrandrine and verapamil on fibroblastic growth and proliferation.粉防己碱和维拉帕米对成纤维细胞生长和增殖的影响。
World J Gastroenterol. 1997 Jun 15;3(2):68. doi: 10.3748/wjg.v3.i2.68.
2
Clinical and experimental study of effect of Raondix Salviae Militiorrhiza and other blood-activating and stasis-eliminating Chinese herbs on hemodynamics of portal hypertension.丹参及其他活血化瘀中药对门静脉高压血流动力学影响的临床与实验研究
World J Gastroenterol. 1998 Oct;4(5):439-442. doi: 10.3748/wjg.v4.i5.439.
3
Cloning of the rat ADAMTS-1 gene and its down regulation in endothelial cells in cirrhotic rats.
Liver. 2000 Apr;20(2):165-72. doi: 10.1034/j.1600-0676.2000.020002165.x.
4
A p160ROCK-specific inhibitor, Y-27632, attenuates rat hepatic stellate cell growth.一种p160ROCK特异性抑制剂Y-27632可减弱大鼠肝星状细胞的生长。
J Hepatol. 2000 May;32(5):762-70. doi: 10.1016/s0168-8278(00)80245-7.
5
An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis.口服内皮素-A受体拮抗剂可阻断晚期大鼠肝纤维化中的胶原蛋白合成与沉积。
Gastroenterology. 2000 Jun;118(6):1169-78. doi: 10.1016/s0016-5085(00)70370-2.
6
7
Tyrosine phosphorylation of focal adhesion kinase by PDGF is dependent on ras in human hepatic stellate cells.血小板衍生生长因子诱导的人肝星状细胞中粘着斑激酶的酪氨酸磷酸化依赖于Ras。
Hepatology. 2000 Jan;31(1):131-40. doi: 10.1002/hep.510310121.
8
Extracellular signal-regulated kinase activation differentially regulates platelet-derived growth factor's actions in hepatic stellate cells, and is induced by in vivo liver injury in the rat.
Hepatology. 1999 Oct;30(4):951-8. doi: 10.1002/hep.510300406.
9
Biological effects of C-type natriuretic peptide in human myofibroblastic hepatic stellate cells.C型利钠肽在人肌成纤维细胞样肝星状细胞中的生物学效应
J Biol Chem. 1999 Aug 20;274(34):23761-9. doi: 10.1074/jbc.274.34.23761.
10
Liver fibrogenesis and the role of hepatic stellate cells: new insights and prospects for therapy.肝纤维化形成及肝星状细胞的作用：新见解与治疗前景
J Gastroenterol Hepatol. 1999 Jul;14(7):618-33. doi: 10.1046/j.1440-1746.1999.01928.x.
Zotero 插件